The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus

被引:45
作者
Delate, T
Coons, SJ
机构
[1] Univ Arizona, Hlth Sci Ctr, Coll Pharm,Grad Program, Dept Pharmaceut Sci, Tucson, AZ 85721 USA
[2] Univ Arizona, Coll Pharm, Div Social & Adm Sci, Tucson, AZ 85721 USA
[3] Univ Arizona, Coll Pharm, Div HIV Policy & Outcomes Res, Tucson, AZ 85721 USA
关键词
D O I
10.1086/318492
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The purpose of this analysis was to examine the ability of the MOS-HIV (Medical Outcomes Study-Human Immunodeficiency Virus) Health Survey and the EuroQol Group's EQ-5D questionnaire to discriminate between subjects in predefined disease-severity groups on the basis of clinical-indicator status (i.e., CD4 cell counts, HIV type 1 [HIV-1] RNA copies). This study used medical records of and instruments completed by 242 HIV-infected patients. The ability of the health-related quality-of-life instruments to discriminate between subjects stratified by disease severity was assessed by means of receiver-operating characteristic (ROC) curve analysis. The EQ-5D (P < .05) and MOS-HIV physical health summary (PHS) scores (P < .01) were able to discriminate between groups of subjects stratified by disease severity on the basis of either CD4 cell counts or HIV-1 RNA copies. These findings provide further evidence of the validity of the use of EQ-5D and the MOS-HIV questionnaire and suggest that they may be practical tools for the monitoring of health status from the HIV-infected patient's perspective.
引用
收藏
页码:E47 / E52
页数:6
相关论文
共 29 条
[1]  
BERZON RA, 1998, MONITOR MED OUTCOMES, V3, P1
[2]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86
[3]   A comparative review of generic quality-of-life instruments [J].
Coons, SJ ;
Rao, S ;
Keininger, DL ;
Hays, RD .
PHARMACOECONOMICS, 2000, 17 (01) :13-35
[4]  
COONS SJ, 1996, PRINCIPLES PHARMACOE, P102
[5]   The use of two measures of health-related quality of life in HIV-infected individuals: A cross-sectional comparison [J].
Copfer, AE ;
Ampel, NM ;
Hughes, TE ;
Gregor, KJ ;
Dols, CL ;
Coons, SJ ;
Colgan, K ;
Wu, AW .
QUALITY OF LIFE RESEARCH, 1996, 5 (02) :281-286
[6]  
Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
[7]   HEALTH-RELATED QUALITY-OF-LIFE EVALUATION IN HIV-INFECTED PATIENTS - A REVIEW OF THE LITERATURE [J].
DEBOER, JB ;
VANDAM, FSAM ;
SPRANGERS, MAG .
PHARMACOECONOMICS, 1995, 8 (04) :291-304
[8]  
Dolan P., 1995, SOCIAL TARIFF EUROQO
[9]   An empirical comparison of four generic health status measures - The Nottingham Health Profile, the Medical Outcomes Study 36-item Short-Form Health Survey, the COOP/WONCA charts, and the EuroQol instrument [J].
EssinkBot, ML ;
Krabbe, PFM ;
Bonsel, GJ ;
Aaronson, NK .
MEDICAL CARE, 1997, 35 (05) :522-537
[10]  
FAUCI AS, 2000, GUIDELINES USE ANTIR